First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma

Trial Profile

First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs IVAC-M-uID (Primary) ; RBL 001/RBL 002 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Sponsors BioNTech; Ribological
  • Most Recent Events

    • 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 05 Jul 2017 According to a BioNTech media release, results from the study have been published online in Nature.
    • 05 Jul 2017 Results published in a BioNTech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top